AI assistant
Sending…
Cidara Therapeutics, Inc. — Director's Dealing 2021
Mar 20, 2021
31535_dirs_2021-03-19_a0e1b6c6-8218-4a39-b25a-fb21f0a898c6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cidara Therapeutics, Inc. (CDTX)
CIK: 0001610618
Period of Report: 2021-03-17
Reporting Person: Abdollahian Neil (Chief Business Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-03-17 | Employee Stock Option (right to buy) | $2.55 | A | 150000 | Acquired | 2031-03-16 | Common Stock (150000.0) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 58308 | Direct |
Footnotes
F1: Includes 8,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 20, 2020 and November 20, 2020.
F2: The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 17, 2021.
More from Cidara Therapeutics, Inc.
Major Shareholding Notification
2026
Feb 17
Major Shareholding Notification
2026
Feb 17
Major Shareholding Notification
2026
Feb 13
Major Shareholding Notification
2026
Jan 30
Regulatory Filings
2026
Jan 12
Regulatory Filings
2026
Jan 12
Regulatory Filings
2026
Jan 12
Regulatory Filings
2026
Jan 12
Regulatory Filings
2026
Jan 12
Regulatory Filings
2026
Jan 12